Table 3.
Studies reporting drug susceptibility of P. kudriavzevii.
| Author | Year | Study design | Study period | Country | Level of care | Population description | Number of patients | Number of isolates | Number of P. kudriavzevii isolates | Samples collected from | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Arendrup27 | 2013 | Prospective national surveillance study | Multi-centre | 2010-2011 | Denmark | Tertiary | Patients with fungaemia | 995 | 1081 fungal isolates | 52 | Blood |
| Arikan-Akdagli75 | 2019 | Retrospective cohort study | Multi-centre | 1997-2017 | Turkey | Tertiary | Candida spp. isolates from 12 centres | ND | 1991 Candida spp. | 52 | Blood |
| Badiee19 | 2017 | Cross sectional study | Multi-centre | 2014-2015 | Iran | Tertiary | Immunocompromised patients admitted to 10 hospitals in Iran | ND | 846 Candida spp. | 23 | Various sites (blood, CSF, bronchoalveolar lavage, and sputum) |
| Castanheira28 | 2020 | Global surveillance study | Multi-centre | 01/2016-12/2017 | Asia Pacific, Europe, Latin America, North America | Tertiary | Patients with Candida infections (from 60 hospitals in 25 countries) | 2936 | 2936 Candida spp. | 76 | Various sites (majority blood) |
| Castanheira29 | 2014 | Global surveillance study | Multi-centre | 2012 | Europe, Latin America, North America and the Asia-Pacific Region | Tertiary | Patients with invasive fungal infections | ND | 1717 | 36 | Various (blood, sterile body fluids, tissues, abscesses, respiratory tract) |
| Castanheira24 | 2014 | Cross sectional study | Multi-centre | 2012 | North America, Europe, Latin America, and the Asia Pacific region | Tertiary | Patients with Candida spp. infection (from 75 medical centres globally) | ND | 1421 | 32 | Various (blood, sterile body fluids, tissues, abscesses) |
| Chen77 | 2017 | Retrospective cohort study | Single centre | 01/2007-12/2012 | Taiwan | Tertiary | Patients with candidaemia | ND | 709 Candida spp. | 13 | Blood |
| Desnos-Ollivier78 | 2019 | Retrospective cohort study | Multi-centre | 01/2015-10/2017 | France | Tertiary | Patients with invasive infections | ND | 1457 | 76 | Blood (majority), CSF, and other |
| Fuller36 | 2019 | Prospective cohort study | Multi-centre | 01/2011-10/2016 | Canada | Tertiary | Patients with bloodstream infections | ND | 1882 Candida spp. | 81 | Blood |
| Seyoum26 | 2020 | Retrospective cohort study | Multi-centre | 01/2018-09/2018 | Ethiopia | Patients with yeast isolated | ND | 209 yeast | 14 | ||
| Hrabovsky79 | 2017 | Retrospective cohort study | Single centre | 01/2013-06/2015 | Slovakia | Tertiary | Adult non-neutropenic ICU patients | 426 | 800 yeasts | 69 | Sterile (n = 101), non-sterile body sites (n = 699) |
| Israel21 | 2019 | Retrospective cohort study | Multi-centre | 01/2005-12/2016 | Israel | Tertiary and secondary | Patients with candidaemia | 899 | 919 Candida spp. | 54 | Blood |
| Kaur12 | 2020 | Retrospective cohort study | Single centre | 01/2014-12/2014 | India | Tertiary | Adult and paediatric patients with candidaemia | 316 (n = 186 paediatric, 130 adults) | 316 Candida spp. | 96 | Blood |
| Kaur23 | 2020 | Retrospective cohort study | Single centre | 01/1999-12/2018 | India | Tertiary | Patients with candidaemia | 7927 | 7927 | 527 | Blood |
| Omrani14 | 2014 | Retrospective cohort study | Single centre | 01/2003-12/2012 | Saudi Arabia | Tertiary | Patients with invasive Candida infections | 652 | 800 Candida spp. | 9 | Sterile sites (blood, CSF, other body fluid, tissue biopsies) |
| Pfaller80 | 2011 | Retrospective cohort study | Multi-centre | 01/2008-12/2009 | Asia-Pacific (16 centres, 51 isolates), European (25 centres, 750 isolates), Latin American (10 centres, 348 isolates) and North American (28 centres, 936 isolates) regions. | Tertiary | Patients with candidaemia reported under global surveillance | 1752 | 1752 | 36 | Blood |
| Pfaller25 | 2015 | Retrospective cohort study | Multi-centre | 2013 | North America (695 isolates, 29 sites), Europe (511 isolates, 19 sites), the Asia-Pacific region (222 isolates, 12 sites), and Latin America (185 isolates, 10sites). | Tertiary | Patients with invasive fungal infections | 1320 | 1320 Candida spp. | 37 | Blood (majority), sterile body fluids (CSF, pleural and peritoneal fluids), tissues, abscesses, respiratory tract and other |
| Salse81 | 2019 | Retrospective cohort study | Multi-centre | 2004-2018 | France | Tertiary | Patients with infections by yeast and Aspergillus fumigatus species from 12 French hospitals | ND | 575 | 575 | Blood, sterile sites and other sites, such as bronchoalveolar lavage, sputum |
| Sasso37 | 2017 | Retrospective cohort study | Single centre | 2007-2016 | France | Tertiary | ICU patients with invasive Candida infections | 244 | 3557 | 192 | Blood, other sterile sites |
| Tóth22 | 2019 | Retrospective cohort study | Single centre | 01/2005-12/2018 | Hungary | Tertiary | Patients with P. kudriavzevii isolates collected | 53 | 53 | 53 | Sterile body sites (blood, cerebrospinal, pleural and peritoneal fluids, deep wounds, etc.) |
CSF=cerebrospinal fluid, ND=no data, ICU=intensive care unit.